tirzepatide blindness weight loss study once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Tirzepatide leads to greater weight – fsa tirzepatide 🌐 https://t.co/lqtXJrdlFg Buy More and Save:4 Bottles GLP-1 (S)

tirzepatide blindness weight loss study once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Tirzepatide leads to greater weight – fsa tirzepatide 🌐 https://t.co/lqtXJrdlFg Buy More and Save:4 Bottles GLP-1 (S)

fsa tirzepatide 🌐 https://t.co/lqtXJrdlFg ✨ Make 2026 Your Breakthrough Year 📦 Simple

In the span of three months, Wegovy (injectable and oral) drove the most weight loss, followed by Ozempic and Rybelsus

GLP-1 (S)

Buy More and Save:4 Bottles

Important safety considerations include an increased risk of hypoglycemia when used with insulin or sulfonylureas, and a boxed warning about thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)